29 Comments
 
Controversial

Recent exits from Gugg: Advent, HIG (multiple), BX, BX Growth, KKR (multiple), Carlyle (multiple), TA Associates as far as big time places. These are recent exits, obviously not all from this year

 

Has the sentiment on medtech changed? You didn’t list in your top groups even though they’ve been regarded very highly in the recent years. Just wondering what’s changed

 

Structured Products is a great group. Probably the best group for Esoteric ABS. They are filled with Lehman/Barclays bankers from the old days and turn anything into a security. Hours are bad but exits are top notch. AFter building models based on 10 page waterfalls for 2-3 years, you'll have the skillset to model any product in existence.

 

It's a good bank that pays well. Definitely an offer worth considering. HC and TMT are strong groups. I'd say their trajectory looks solid. I'd view Jefferies and Greenhill as their best comps (latter trending downward but still exiting well). I wouldn't say they are quite at the same level as PWP / MOE / LAZ but they are still great.

FWIW, I work at a UMM fund that hired a Guggenheim analyst during this past on cycle process (top group, target school, perfect stats, etc.) and interviewed a few more (all from HC / Biopharma / TMT). Think we still tend to interview more kids from mid-tier BBs like Barclays though.

 

RX group has good exits, including Monarch, Beachpoint, CVC, Lonestar, Melvin (RIP), Caspian, Diameter, PIMCO, etc.

 

Any updates on Gugg placement this past on-cycle? Heard there were some CD&R placements

 

Distinctio neque nostrum esse. Quae eius quod est est similique ut eveniet placeat. Veritatis totam minus ducimus aut quos beatae. Maxime dolorem aspernatur facilis aut est quam enim qui. Et est magni at similique et est. Magnam in quaerat molestiae velit est aut.

Nam numquam quisquam ut voluptas possimus est facilis. Est sunt aut facilis eos sint. Dicta similique porro optio cum saepe. Voluptatem velit eos non.

Qui magni nihil natus dolor exercitationem. Nulla velit quasi vero excepturi. Veniam cumque dolorem unde.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (68) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”